header logo image


Page 18«..10..17181920..3040..»

Archive for the ‘Diabetes’ Category

Recreational marijuana use may have negative impact on diabetes, review finds – The GrowthOp

Thursday, August 20th, 2020

Recreational cannabis may not pair well with diabetes, according to a review of recent studies that examined the effects of the drug on people living with type 1 or type 2 versions of the disease.

The review, which was commissioned by Diabetes Canada, narrowed its focus to six observational studies in an attempt to better understand the interaction between cannabis and the disease that prevents people from producing insulin or properly using the insulin it produces. The results were not encouraging.

Recreational cannabis use may negatively impact diabetes metabolic factors and self-management behaviours in people with T1D, the researchers noted. In people with T2D, recreational cannabis may increase risks for peripheral arterial occlusion, myocardial infarction and renal disease, they added.

Five of the studies examined found that cannabis use led to reports of higher glycated hemoglobin (HbA1c) with one in particular finding that cannabis use within the previous 12 months was associated with almost double the risk of diabetic ketoacidosis compared with no cannabis use. Another study found that cannabis-using students with type 1 diabetes between the ages of 17 and 25 self-reported poorer glycemic control and elevated glycated hemoglobin.

The concerning findings were not limited to type 1 incidents of the disease. Risks for peripheral arterial occlusion and myocardial infarction were found to be higher in people with type 2 diabetes who consumed recreational cannabis, and worse renal parameters were also reported in two separate studies of T1D and T2D.

The concerning findings were not limited to type 1 incidents of the disease. / Photo: ~UserGI15994093 / iStock / Getty Images Plus/ Photo: ~UserGI15994093 / iStock / Getty Images Plus

Because the rapid review was limited to just six studies of poor to fair methodological quality, the researchers recommend further robust, higher quality research are needed to confirm the findings.

Senior citizens with a diabetes diagnosis are on the rise in the U.S. According toThe American Diabetes Association, 14.3 million seniors (26.8 per cent) have diabetes (diagnosed or undiagnosed). In a 2017 report, theCenters for Disease Control and Prevention found that more than 100 million people in the U.S. were at risk for diabetes.

Here at home, one in three Canadians is currently living with diabetes or prediabetes, according to Diabetes Canada, which hopes to use the review findings to inform recommendations for people over the age of 13 who are living with the disease.

Want to keep up to date on whats happening in the world of cannabis? Subscribeto the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.

Visit link:
Recreational marijuana use may have negative impact on diabetes, review finds - The GrowthOp

Read More...

Non-Insulin Therapies for Diabetes Market: In-depth Analysis of the Global Industry with Future Estimations till 2029 – The Daily Chronicle

Thursday, August 20th, 2020

The Non-Insulin Therapies for Diabetes Market Research Report published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Non-Insulin Therapies for Diabetes market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Non-Insulin Therapies for Diabetes market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

PANDEMIC OFFER GOING ON YOU CAN WIN HUGE DISCOUNTS ON LATEST MARKET RESEARCH REPORTS

The facts and data are represented in the Non-Insulin Therapies for Diabetes report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/55

The research report also focuses on global major leading industry players of Non-Insulin Therapies for Diabetes market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Non-Insulin Therapies for DiabetesMarket Key Companies:

AstraZeneca, Bristol-Myers Squibb, BoehringerIngelheim GmbH, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Merck and Company, Janssen Pharmaceuticals, Novartis AG, Sanofi Aventis, Novo Nordisk, Pfizer and Takeda Pharmaceuticals.

The predictions mentioned in the Non-Insulin Therapies for Diabetes market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Segmentation Overview:

The report provides an in-depth analysis of the Non-Insulin Therapies for Diabetes market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/55

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Original post:
Non-Insulin Therapies for Diabetes Market: In-depth Analysis of the Global Industry with Future Estimations till 2029 - The Daily Chronicle

Read More...

Metformin Use Linked to Early Risk of Anaemia in Type 2 Diabetes – Medscape

Thursday, August 20th, 2020

Takeaway

Metformin use was associated with an early reduction in haemoglobin (Hb) and increased rates of moderate anaemia in patients with type 2 diabetes (T2D), and this finding was consistent across two randomised controlled trials (RCTs) and replicated in one real-world study of routinely collected data.

Why this matters

Because the mechanisms for metformin-related moderate anaemia are unknown, the effects are modest, and the benefits of metformin are proven, the authors do not advocate avoidance or discontinuation even in patients with anaemia, but a reduction in Hb in the first few years after initiation might be anticipated.

Study design

Association between metformin use and anaemia risk in T2Dand the time course for thiswere evaluated in the A Diabetes Outcome Progression Trial (ADOPT; n=3967) and UK Prospective Diabetes Study (UKPDS; n=1473) RCTs.

The cumulative effect was evaluated in the observational Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) population (n=3485).

Funding: Medical Research Council.

Key results

In ADOPT, compared with sulphonylureas, the OR for anaemia was 1.93 (95% CI, 1.10-3.38) for metformin and 4.18 (95% CI, 2.50-7.00) for thiazolidinediones (TZDs).

In UKPDS, compared with diet, the OR for anaemia was 3.40 (95% CI, 1.98-5.83) for metformin, 0.96 (95% CI, 0.57-1.62) for sulphonylureasand 1.08 (95% CI, 0.62-1.87) for insulin.

In ADOPT, Hb and haematocrit levels dropped by 6 months in both metformin and TZDs groups with no further Hb decrease between 3 and 5 years.

In UKPDS, Hb levels dropped by 3 years with metformin treatment vs other treatments.

At 6 and 9 years, Hb levels were reduced in all treatment groups with no greater further fall seen in the metformin vs diet-treated group (0.49 g/dL [95% CI, -1.64 to 2.62] vs 0.50 g/dL [95% CI, -1.71 to 2.72] fall from 3 to 9 years).

In GoDARTS, each 1 g/day of metformin use was associated with a 2% increased annual risk of anaemia.

Limitations

Donnelly LA, Dennis JM, Coleman RL, Sattar N, Hattersley AT, Holman RR, Pearson ER. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. Diabetes Care. 2020 Aug 14 [Epub ahead of print]. doi: 10.2337/dc20-1104. PMID: 32801130. View abstract.

This clinical summary first appeared on Univadis, part of the Medscape Professional Network.

Cite this: Metformin Use Linkedto Early Risk of Anaemia in Type 2 Diabetes-Medscape-Aug19,2020.

The rest is here:
Metformin Use Linked to Early Risk of Anaemia in Type 2 Diabetes - Medscape

Read More...

Peanuts for a diabetic diet – Is it safe? How to include them in your food to keep blood sugar managed – Times Now

Thursday, August 20th, 2020

Peanuts for a diabetic diet - Is it safe? How to include them in your food to keep blood sugar managed | Photo Credits: Canva 

New Delhi: Diabetes is a condition that is best managed with the help of the right, healthy diet, and regular exercise. While people with diabetes may need insulin shots, or medicines to regulate blood sugar levels, if they refuse to cut out foods that are rich in sugar from their diet, they are likely to experience complications due to the disease.

Diabetes is a health condition characterised by a spike in blood sugar levels. While the reasons for this can differ, which determines the type of diabetes, a healthy, regulated diet remains key for management of the condition, irrespective of the type. While certain foods are clearly not fit for diabetics for very obvious reasons such as crystal sugar, other foods often leave diabetics and their caretakers confused as to if they are safe or not.

Peanuts are a legume that originated in South America. While a lot of people mistake them to be of Indian origin, they are often called groundnuts in the country. They come from the family of legumes and are related to beans, lentils, soy, etc. Many people, especially in the US, are also allergic to peanuts and food products made with it.

Going by the family they come from, one can assume that peanuts may be safe for diabetics. While some legumes may contain some carbs, they are not bad carbs and are therefore not likely to affect your blood sugar levels adversely.

According to the National Peanut Board, people with diabetes can consume peanut and peanut butter to manage blood sugar levels, provided they are not allergic. Both peanuts and peanut butter have a low glycemic index of 13, which is well within the safe range of GI for diabetes patients.

Peanuts chaat Peanuts chaat can be consumed on a weight loss or diabetic diet. Dry roast some peanuts, add veggies such as onions and tomato, some lemon juice and season it with salt. It can serve as a quick breakfast and mid-day recipe.

Peanut butter sandwich Peanut butter is a source of healthy fats, and is great for a weight loss or diabetic diet snack. You can add peanut butter to smoothies and shakes, and may also make a sandwich with multi-grain bread to enjoy as an evening snack.

Peanut Poha Poha is flattened rice, consumed very commonly in Indian households as a popular breakfast. You can add peanuts to the poha to increase its nutrient content.

Blueberry Peanut Smoothie - A recipe you must try for all those busy mornings as the flavours of berries and peanut butter mingle together and go well with each other. This will help you get an antioxidant punch right at the beginning of the day, which makes it perfect for a breakfast meal.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read more:
Peanuts for a diabetic diet - Is it safe? How to include them in your food to keep blood sugar managed - Times Now

Read More...

New Onset Diabetes and Weight Loss Associated with Pancreatic Cancer Risk – DocWire News

Thursday, August 20th, 2020

A new study observed a correlation between newly diagnosed diabetes and recent weight loss and an increased likelihood of pancreatic cancer.

Despite pancreatic cancers status as the third leading cause of cancer deaths in the United States, there is a scarcity of research on high-risk groups; such data could help would be helpful in achieving early diagnoses, according to the authors of the present study.

The researchers identified data from the Nurses Health Study and Health Professionals Follow-Up Study; repeated exposure assessments were performed over 30 years. Pancreatic cancer cases were either self-reported or discovered during follow-up of participant deaths, which were determined through next of kin reports, the US postal service, or the National Death Index. Exposures were the duration of diagnosed diabetes and recent weight change; the main outcome was the hazard ratio (HR) of developing pancreatic cancer.

Final analysis included 112,818 women (mean age, 59.4 years) and 46,207 men (mean age, 64.7 years); 1,116 total pancreatic cancer incidents were identified. When adjusting for age, patients with recent-onset diabetes, compared to nondiabetic patients, were more likely to have pancreatic cancer (HR=2.97; 95% confidence interval [CI], 2.31 to 3.82), as were long-standing diabetics (HR=2.16; 95% CI, 1.78 to 2.60). Compared to patients who did not lose weight, in age-adjusted analyses, the risk of pancreatic cancer was greater among patients with a weight loss of 1 to 4 pounds (HR=1.25; 95% CI, 1.03 to 1.52), 5 to 8 pounds (HR=1.33; 95% CI, 1.06 to 1.66), and more than 8 pounds (HR=1.92; 95% CI, 1.58 to 2.32). Pancreatic cancer risk was significantly higher among recent-onset diabetes patients reporting a weight loss between 1 and 8 pounds (91 incident cases per 100,000 person years; 95% CI, 55 to 151; HR=3.61; 95% CI, 2.14 to 6.10) or more than 8 pounds (164 incident cases per 100,000 person-years; 95% CI, 114 to 238; HR=6.75; 95% CI, 4.55 to 10.00) compared to non-diabetic patients with no recent weight loss (16 cases per 100,000 person-years; 95% CI, 14 to 17). Pancreatic cancer incidence was greatest among recent-onset diabetes patients with weight loss whose body mass index was <25 kg/m2 before weight loss (400 incident cases per 100,000 person-years) or whose weight loss was unintentional based on increased physical activity or healthier dietary choices (334 incident cases per 100,000 person-years).

The study was published in JAMA Oncology.

This study demonstrates that recent-onset diabetes accompanied by weight loss is associated with a substantially increased risk for developing pancreatic cancer. Older age, previous healthy weight, and no intentional weight loss further elevate this risk, the authors concluded.

See original here:
New Onset Diabetes and Weight Loss Associated with Pancreatic Cancer Risk - DocWire News

Read More...

Join John and Tammy for the 3rd Annual Dance for Diabetes – RADIO.COM

Monday, August 17th, 2020

In light of the COVID-19 pandemic, and to protect the type 1 diabetes (T1D) community, the Diabetes Research Connection (DRC) is going virtual with its 3rd annual Dance for Diabetes Under the Sea. John and Tammy in the Morningwill be hosting this event on September 30th at 6pmPT!

The event is FREE and will feature RaeLynn, Uncle Kracker, Tim McGraw, and more!

The Dance for Diabetes will raise necessary funds to support DRCs mission to connect donors with early-career scientists enabling them to perform peer-reviewed, novel research designed to prevent and cure T1D, minimize its complications and improve the quality of life for those living with the disease. Currently, 1.6 million Americans live with this autoimmune disease, including 200,000 children. Approximately 40,000 new patients are diagnosed yearly. Despite these numbers, funding for diabetes research has declined. Of the funding available, 97% goes to established scientists.

Go to diabetesresearchconnection.org/dancefordiabetes to RSVP!

See the rest here:
Join John and Tammy for the 3rd Annual Dance for Diabetes - RADIO.COM

Read More...

Amid COVID-19 pandemic, people with diabetes struggle to get insulin – Press of Atlantic City

Monday, August 17th, 2020

LOS ANGELES For Adam Winney, a 26-year old with Type 1 diabetes, grocery shopping during the early days of a pandemic was an infuriating task. Everything was sold out, except for the one type of food he couldnt eat.

The only things left were carbs, carbs, carbs, the Van Nuys resident said. Ive never been more furious than back in March.

Winneys disease has deprived his body of insulin, a hormone thats needed to turn the sugar in carbohydrates into energy. Without it, his blood sugar can spike to dangerous levels, eventually leading to serious health problems like cardiovascular disease, nerve damage and kidney failure.

But the insulin pens he relies on to keep his body in balance cost him upwards of $1,000 a month, since his health insurance doesnt cover the medication.

After the coronavirus outbreak cost him his job as a receptionist at a hair salon, that expense was beyond his reach. He went six weeks without the long-acting insulin he usually takes every day.

COVID-19 presents a unique set of challenges to the roughly 34 million Americans like Winney who are living with diabetes.

The Centers for Disease Control and Prevention says people with Type 1 diabetes are probably more susceptible to a severe case of COVID-19. Those with Type 2 diabetes the more common form that begins when people lose their sensitivity to insulin are definitely at increased risk of severe COVID-19, according to the CDC.

For instance, a study of more than 7,300 COVID-19 patients in China found that those with Type 2 diabetes needed more medical care and were nearly 50% more likely to die than patients without diabetes.

The risk of death was especially high for people who had trouble controlling their blood sugar, researchers reported. Another study of more than 1,200 COVID-19 patients in the U.S. found that the mortality rate for those with diabetes or high blood sugar was 29%, compared with 6% for those without diabetes.

The extent to which you control your diabetes is a risk factor, said Dr. Daniel Drucker, a senior scientist at the Lunenfeld-Tanenbaum Research Institute at the University of Toronto. Theres a lot we can do about that, by making sure that your diabetes is optimally controlled.

Insulin is essential for keeping blood sugar in check, but the pricey medicine is harder to get if a job disappears, along with the health insurance that came with it.

The cost of insulin varies from patient to patient. It depends on the type of insulin they need some take effect within 15 minutes; others last more than a day _ as well as the dose. Some insurance plans pick up more of the tab than others.

The financial strain brought on by the pandemic has forced Royce Jonathan Miller of Yuba City to consider rationing the insulin he takes for Type 1 diabetes. He has kept his job as an optician at Walmart, but since his father-in-law lost his job at a maintenance company that closed operations due to the pandemic, Miller has become the sole provider for the four people in his household.

Miller has an insulin pump, which uses a tube to continuously deliver a small amount of insulin directly to the pancreas. He is supposed to change out the pieces that connect to his body every three days. Lately, hes been wondering if thats absolutely necessary.

Im starting to think, I can stretch that up for two cycles, every six days, and hopefully it doesnt get infected, Miller said. But I do realize that if I am to make myself sick and wind up in the hospital, that will be a bigger burden.

A nationwide survey of 5,000 people with diabetes conducted for the American Diabetes Assn. found that one in four have rationed supplies to cut the cost of their diabetes care since the start of the pandemic.

Now is not the time to let up on helping these individuals manage their disease, because it may in fact be helpful in preventing them from getting severe COVID-19, Drucker said.

People with Type 2 diabetes may face even greater hardship in affording their insulin, said Dr. Francisco Prieto, a family health physician in Sacramento.

Not everyone who has Type 2 has to take insulin, Prieto said. Those who do are typically folks who either have the most severe cases of diabetes or have failed all the previous oral and injectable treatments. That means they may need to take even more insulin on a daily basis than Type 1 patients, he said.

Since 2019, 11 states have set limits on the amount insurance companies can set as co-payments for insulin. Each of those states has enacted price caps ranging from $25 to $100 per month since the coronavirus outbreak took off in March.

California may soon join the list. In February, Assemblyman Adrin Nazarian, D-North Hollywood, introduced a bill that would cap insulin copays at $50 for a 30-day supply, or $100 per month. It passed in June by a 64-4-11 vote, but the Senate Health Committee has not scheduled a hearing that would allow the bill to move forward.

Winney said a price cap would give him some peace of mind. These days he relies on free samples provided by one of his doctors, but that generosity may not last.

I see that as an incentive to finally change insurance, he said.

Ensuring an affordable supply of insulin would help people with diabetes manage their disease better, said Brandi DaVeiga, a stay-at-home mom in Lakewood with Type 1 diabetes. She has good coverage now through her husbands health insurance plan, but when she was between plans three years ago, she began skipping insulin doses to make her supply last longer. On several occasions, her blood sugar levels rose dangerously high, and she ended up in the emergency room.

Its really stressful, she said of managing diabetes during a pandemic. And that doesnt help your blood sugar.

The fact that people with diabetes are rationing their insulin when they need it most points to larger problems with health care access in this country, Drucker said.

COVID-19 is reminding us of the importance of doing everything we can in our vulnerable, at-risk populations, he said. Lets do everything we can to optimize their health because that may, in turn, reduce their risk of having a bad outcome with this virus.

See the original post here:
Amid COVID-19 pandemic, people with diabetes struggle to get insulin - Press of Atlantic City

Read More...

Non-invasive Blood Glucose Monitoring Devices Market: Wearable segment dominated the global market in terms of revenue – BioSpace

Monday, August 17th, 2020

Non-invasive Blood Glucose Monitoring Devices Market: Introduction

Diabetes is a chronic disease that affects more than 8.5% of the global population. Monitoring the blood glucose levels (BGLs) on a regular basis is necessary to manage diabetes progression. Non-invasive blood glucose monitoring devices use painless procedure for continuous tracking of a patients glucose level. Increase in demand for smart diabetes management devices due to the technologically advanced features is anticipated to drive the market.

Read Report Overview - https://www.transparencymarketresearch.com/noninvasive-blood-glucose-monitoring-devices-market.html

Key Drivers and Restraints of Global Non-invasive Blood Glucose Monitoring Devices Market

Diabetes has evolved as one of the principal health care epidemics of the modern era. Prevalence of diabetes is rising due to change in lifestyle, environmental factors, and genetic mutation. Moreover, obesity is a key risk factor for diabetes. According to the American Diabetes Association, an estimated 30.3 million people in the U.S. had diabetes in 2015; among these 1.25 million were children. According to the British Diabetic Association operating as Diabetes UK, 3.8 million people were diagnosed with diabetes in the U.K. in 2019. According to Diabetes U.K., 382 million adults across the globe aged between 20 and 79 had diabetes in 2012. This number is expected to reach 592 million by 2035. An estimated 175 million people are undiagnosed with type 2 diabetes. Prevalence of diabetes is variable and is expected to increase in the near future.

Continuous advancement in technologies also boosts market growth. Researchers are focusing on electromagnetism (EM) as a leading technology to achieve non-invasive and continuous glucose monitoring. Launch of new products also fuels the growth of the global market. In January 2020, Integrity Applications, Inc. received CE Mark approval for a major enhancement to GlucoTrack, allowing users to perform the calibration process by themselves, without the need of a certified calibrator.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78494

Non-invasive glucose monitoring devices are based on various technologies, which detect characterization of the biological properties of the skin or biological fluids. The accuracy offered by these types of product is not close to that of minimally invasive CGM devices under uncontrolled conditions. This factor is likely to hamper the growth of the global market.

Spectroscopy to Dominate Global Non-invasive Blood Glucose Monitoring Devices Market

In terms of technology, the global non-invasive blood glucose monitoring devices market can be divided into spectroscopy, microwave/RF sensing, electromagnetic, thermal, ultrasonic and others

Spectroscopy technology-based devices dominated the global market in terms of revenue in 2019. The technology is based on the direct effect of glucose on the scattering properties of the organ. Diabetes and its complications impose significant economic consequences on individuals, families, health systems, and countries. This non-invasive process is fast, painless, and cost-effective. OrSense's NBM device is based on occlusion spectroscopy, which is a proprietary technology aimed toward assuring accurate, convenient, and affordable glucose monitoring.

Request for Analysis of COVID-19 Impact on Non-invasive Blood Glucose Monitoring Devices Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78494

Wearable to Lead Global Non-invasive Blood Glucose Monitoring Devices Market

Based on modality, the global non-invasive blood glucose monitoring devices market can be bifurcated into wearable and non-wearable/table-top

The wearable segment dominated the global market in terms of revenue in 2019. Requirement of painless, needle-free, and continuous glucose monitoring sensors to enhance the quality of life of diabetic patients is a major factor driving the segment. AerBetic manufactures a non-invasive wearable diabetes monitor that continuously provides blood sugar levels. It also comes with an application that allows a user to set up alerts in order to communicate to a network of health care providers.

Home Care Segment to Witness Significant Growth

In terms of end user, the global non-invasive blood glucose monitoring devices market can be categorized into hospitals, home care, and clinics

The home care segment held the largest share of the global market in 2019. Advancements in mobile health & connected devices, remote patient monitoring, and telehealth augment the self/home health care management of diabetes. Additionally, preference for treatment of diabetes at home is likely to propel the segment. Inclination toward self-management devices is a key factor projected to drive the segment.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78494

North America to Dominate Global Non-invasive Blood Glucose Monitoring Devices Market

In terms of region, the global non-invasive blood glucose monitoring devices market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

In terms of revenue, North America dominated the global non-invasive blood glucose monitoring devices market in 2019, followed by Europe. High prevalence of diseases and well-established health care infrastructure that enables proper diagnosis are attributed to the regions large market share. According to the American Diabetes Association, in 2018, 34.2 million people in the U.S., or 10.5% of the population, had diabetes. Moreover, 1.6 million people have type 1 diabetes, including about 187,000 children and adolescents.

However, the market in Asia Pacific is expected to grow at a rapid pace during the forecast period primarily due to rise in prevalence of diabetes and increase in awareness about diagnosis & treatment. Majority of countries in Asia Pacific are economically developing and a number of players are making significant investments in the region. These factors boost the growth of the market in Asia Pacific. According to the International Diabetes Federation (IDF), prevalence of diabetes has increased in developing countries due to rapid and ongoing socioeconomic transition and it is likely to rise further.

Pre Book Non-invasive Blood Glucose Monitoring Devices Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=78494&ltype=S

Key Players Operating in Market

The global non-invasive blood glucose monitoring devices market was highly fragmented in 2019. Key players operating in the global market are:

Browse More Trending Reports by Transparency Market Research:

Vaginitis Therapeutics Market: https://www.transparencymarketresearch.com/vaginitis-therapeutics-market.html

Anti allergic Therapeutics Market: https://www.transparencymarketresearch.com/antiallergic-therapeutics-market.html

Aseptic Meningitis Treatment Market: https://www.transparencymarketresearch.com/aseptic-meningitis-treatment-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Go here to read the rest:
Non-invasive Blood Glucose Monitoring Devices Market: Wearable segment dominated the global market in terms of revenue - BioSpace

Read More...

The relationship between diabetes and muscle mass – Open Access Government

Monday, August 17th, 2020

Diabetes, well known as a lifestyle-related disease, represents one of the most common diseases of the modern age with an increasing number of patients every year.

According to a survey by the International Diabetes Federation (IDF), 1 in 11 adults (20-79 years) have diabetes (463 million people) (1). This steady increase in diabetes diagnoses is due, in part, to the obesity epidemic. 87.5% of adults with diabetes are overweight or obese according to their Body Mass Index (BMI). However, these findings make it seem like only those with high weight are at risk for diabetes, but that is not the case. In fact, so-called skinny fat (Sarcopenia), individuals with a normal or low BMI but a high percent body fat, are at an increased risk to develop diabetes or prediabetes. This is why it is important for those looking to reduce diabetes risk or manage their diabetes to understand their body composition.

The term body composition means exactly what it sounds like: the components that your body is made up of. Generally speaking, these components can be simply categorised as fat and fat-free mass. As you might expect, your fat-free mass (FFM) is everything in your body that is not fat. The body generally needs a balance of FFM and fat mass to function optimally and maintain positive health. However, this balance is disrupted in many overweight and obese individuals due to excess fat.

In other words, the goal for overweight individuals should not be to simply lose weight; instead, it should focus on improving body compositionby reducing fat mass while maintaining or increasing FFM.

Not only does a more balanced body composition make you look leaner, but it can also reduce your risk of diabetes and other obesity-related disorders.

Excessive fat mass does not alone increase the risk of diabetes.Various recent research has shown a link between diabetes risk and low muscle mass.The negative effects of Type 2 diabetes (T2D) on muscle can be divided into three categories: fatigue, muscle strength, and muscle mass.

Muscle fatigabilityrefers to the rate at which your muscles become weaker after exercise or movement, and the amount of time it takes for them to recover or return to their full power. Researchers have known for years thatmuscle fatigability increases with T2D (2). When people with T2D perform an exercise, their muscles lose power faster than those of a healthy person.

T2D reduces overallmuscle strengthas well. Even after adjusting for age, sex, education, alcohol consumption, lifetime smoking, obesity, and aerobic physical activity,people with T2D had less handgrip strengththan people without it.

Not only do T2D patients have both reduced muscle recovery and strength, they also start to lose muscle mass. In fact,the longer you have diabetes, the more muscle mass you tend to lose, especially in the legs (3).

InBody results for patients with T2D shows that lower body muscle mass is particularly low.

Heres the good news. If low muscle mass increases the risk of T2D, it is also possible to reduce the risk of Type 2 diabetes by increasing muscle mass and improving body composition. You cantake control of your diabetes riskby improving your body composition.

Research has shown thatincreasing your muscle mass reduces your risk of T2D. In a 2017 study, researchers in Korea and Japan followed over 200,000 otherwise healthy people who had no diabetes or prediabetes at the start of the experiment. After 2.9 years, theparticipants with more muscle mass were significantly less likely to have T2D (4). In fact, exercise is good for reducing diabetes risk as well as improving diabetic state all on its own. This is because exerciseincreases the delivery of glucose to our muscle cells. When you exercise, your muscles are exerting more than their normal energy demand, thus creating a higher need for energy/glucose to fuel them. In fact,resistance traininghas been shown to be particularly beneficial for T2D (5). Larger muscles require more energy, therefore, the leg muscles, being the largest muscles in the body, are especially important for glucose uptake and regulation. Therefore,targeting the legs with resistance exercisemay improve diabetes risk factors as well as promote physical function. As mentioned previously, those who are diagnosed with T2D often lose the most muscle mass in the legs, making leg day all the more important to maintain and build muscle mass to reduce the risk of diabetes.

Although Type 2 diabetics are insulin-resistant, this increased demand for glucose from exercise helps to increase the efficiency of insulin to get glucose into the muscle cells, improving their diabetic state overall!

The major takeaway here is that diabetes is not only a disease that has to do with weight but high body fat and low muscle massbothincrease diabetic risk.

The main goal to reduce this risk or improve diabetic state is to improve body composition. This can be done by reducing body fat for those who are overfat, as well as building muscle for those who have low skeletal muscle mass.

The best thing to do in order to have a better idea of your health risks and create attainable goals for yourself is to get your body composition tested. From there, you can make adjustments to your lifestyle to alter your body composition, if necessary, to reduce your risk for diabetes and other conditions. If you already have T2D or prediabetes,focus on losing fat while engaging the muscles with exercise.

See what youre made of and get started on the path to a healthier life today!

References

(1) IDF Diabetes Atlas 9th International Diabetes Federation.

(2) Mechanisms for the increased fatigability of the lower limb in people with type 2 diabetes, Senefeld J. et al., J Appl Physiol (1985). 2018 Aug 1;125(2):553-566.

(3) Reduction of Skeletal Muscle, Especially in Lower Limbs, in Japanese Type 2 Diabetic Patients With Insulin Resistance and Cardiovascular Risk Factors, Yuji Tajiri et al., Metab Syndr Relat Disord. 2010 Apr;8(2):137-42.

(4) Relative muscle mass and the risk of incident type 2 diabetes: A cohort study, Sungwoo Hong et al., PLoS One. 2017; 12(11): e0188650.

(5) A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes, Castaneda C. et al., Diabetes Care. 2002 Dec;25(12):2335-41.

Please note: this is a commercial profile.

Editor's Recommended Articles

Visit link:
The relationship between diabetes and muscle mass - Open Access Government

Read More...

Technology can help people manage their diabetes case study shows it’s not being used – The Conversation Africa

Monday, August 17th, 2020

Non-communicable diseases are the leading cause of death globally. Theres no cure for most of them, such as diabetes. Rather, theyre controlled through lifelong medical treatment as well as support from healthcare professionals and family members.

Suboptimal treatment of diabetes can lead to severe complications such as amputations, blindness and kidney disease. Thats why ongoing patient self-management education and support are critical to preventing acute complications and reducing the risk of death. This is increasingly important during the COVID-19 pandemic where the treatment and prevention of noncommunicable diseases has been negatively affected, especially in low-income countries. Patients with diabetes are also at higher risk for severe COVID-19 complications and death.

The World Health Assembly recognises the potential for information and communication technology (ICT) to support healthcare systems. ICT can support disease prevention and health promotion by improving affordability, access and quality of health services worldwide. ICT used in health is often referred to as electronic health (e-health). Mobile health (m-health) refers to e-health applications delivered on mobile technology.

Interventions using m-health show promise as it could improve care for patients with chronic conditions. A previous study in Senegal has shown that simple interventions delivered via mobile applications can help to decrease diabetes risk factors such as an unhealthy diet and physical inactivity.

But patients cant benefit from innovations such as apps on mobile phones unless they accept them and use them effectively.

We set out to measure the use of technology for patients with diabetes. Our research was based in low-resourced communities in South Africas Western Cape province.

We wanted to identify factors that influenced peoples choices when it came to using technology to manage their diabetes. A very high percentage of survey participants had high intentions of using technology to assist with diabetes self-care activities such as healthy eating, being active, monitoring, taking medication, problem-solving, healthy coping and reducing risks. But, when it came down to actual use there was very little uptake.

There has been a rapid rise in diabetes globally but the rate has been rising more rapidly in low- and middle-income countries than in high-income countries. South Africa is no exception. South Africas diabetes prevalence in adults is 12.8% compared to the neighbouring country, Zimbabwe at 1.2%.

Diabetes control is also lower among racial and ethnic minorities and especially those with low socioeconomic status. The demographics of the Western Cape reflect the socioeconomic plight of a substantive population. Additionally, segments of the Western Cape population experience technological forms of exclusion on top of educational and income inequalities.

We selected 497 respondents from low-resourced communities in the surrounds of Cape Town. They included Mitchells Plain, Belhar and Khayelitsha. Most were women over the age of 50 with type 2 diabetes. A third of the respondents had Grade 12 as their highest level of education. Just under a fifth had some high schooling. Most spoke English (43.4%) followed by Xhosa (27.7%) and Afrikaans (23.1%). These factors are important as South Africa has diverse populations with significant educational, technological and income inequalities that may impact ICT use for diabetes. South Africa also has 11 official languages which will affect the ability to use m-health applications that are predominantly in English.

We tested whether patients were likely to use ICT to help them manage their diabetes. The model we used looked at four factors:

whether a person believed using the system would be effective (in this case, whether the patient thinks it will improve their health)

whether a person finds it easy to use

whether a person feels that others think they should use it

whether a person thinks the system is supported by conditions such as internet access and a helpdesk to provide support with technical difficulties.

Achieving these four factors increases the possibility that individuals will perform the behaviour in question (behavioural intention). A positive behavioural intention may lead to patients using ICT for diabetes.

Respondents were asked about their use of ICT such as mobile applications, insulin pumps (devices that delivers insulin 24 hours a day to match your bodys needs) and continuous glucose monitoring through a device that provides patients with a glucose reading every few minutes.

Our findings were surprising. Most respondents ticked the four boxes. This would suggest a positive behavioural intention. Yet, their behavioural intention didnt translate into actual usage.

For example, respondents were asked whether they used the above technology to help them manage their diabetes and 68% said they didnt.

We identified a number of contributing factors to the low uptake.

One was limited internet access and difficulty using technology. Age and education also played a role.

Respondents were asked what would make them use ICT more often. Reduced cost, as well as making applications easier to use and understand, were identified as the most critical factors.

Mobile phone applications are effective in managing diabetes in other low- and middle-income countries. But South African data costs exceed other countries. Also, Senegals success can be attributed to the governments involvement in implementing the mobile application.

South Africa will require a similar intervention, such as MomConnect that is available in all 11 languages. The service, free to all users, is independent of mobile device type. Alternatively, the use of WhatsApp as is being used for COVID-19 could be considered to support the growing number of patients with diabetes.

More:
Technology can help people manage their diabetes case study shows it's not being used - The Conversation Africa

Read More...

Nemaura Medical banks $18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services – Proactive Investors USA…

Monday, August 17th, 2020

The UK-based company has developed its continuous glucose monitor sugarBEAT and health subscription service BEATdiabetes

() announced Monday that it has about $18 million in cash to help fund the development and commercialization of its diabetes diagnostic devices and subscription services.

The company said it ended its first quarter on June 30, 2020, with $5.9 million in cash but raised an additional $10.7 million a month later via a fundraising scheme.

Nemaura also noted that it further strengthened its financial position heading into its current second quarterby reducing research and development as well as general and administrative expenses in April, May and June.During itsfirst-quarter, it also narrowed its comprehensive loss to $1.095 million compared to a loss of $1.267 million in the year-ago quarter.

We continue to make significant strides towards our commercial goals of diabetes prevention and management, and this quarter we secured sufficient capital to support our planned product launch in the USA, UK and Germany, demonstrating investor confidence in the company, its management and its product pipeline, Nemaura CEO Faz Chodhury said in a statement.

Nemaura, based in Loughborough, is developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT, its non-invasive and flexible continuous glucose monitor.

The devices and sugarBEAT are offered in conjunction with BEATdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching.

Contact the author: [emailprotected]

Follow him on Twitter @PatrickMGraham

Continue reading here:
Nemaura Medical banks $18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services - Proactive Investors USA...

Read More...

Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment…

Monday, August 17th, 2020

Investigational first-in-class glucokinase activator, with a novel mode of action, focused on fixing the glucose sensor and restoring glucose homeostasis for Type 2 diabetes mellitus (T2DM) patients, with sustained efficacy in phase III clinical trial in Chinese T2DM patients. 116 million T2DM patients in China, with an unsatisfied treatment and control rate. Agreement further strengthens Bayers diabetes management leadership in China.

Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. The agreement aims to provide Chinese diabetes patients with access to a new treatment option, building on Bayers existing strength and leadership in diabetes management in China and the innovation capabilities of Hua Medicine.

Bayer has been long committed to Chinese patients living with diabetes and diabetic macular edema (DME) by offering innovative treatment options including Glucobay and Eylea, said Wei Jiang, Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC and President of Bayer Group Greater China. In the face of significantly increasing challenges caused by diabetes to public health in China, our collaboration with Hua Medicine will further address unmet medical needs of Chinese patients living with diabetes. By leveraging Bayers well-established products as well as the upcoming continuous glucose monitoring system under the partnership with WaveForm, we will be able to provide integrated solutions ranging from prevention, diagnosis, treatment and complication management.

Type 2 diabetes continues to be an important health challenge. According to the China Mainland National Cross Sectional Study in the British Medical Journal, the prevalence rate of T2DM for adults in China is 11.2%, but the proportion of patients who have their hemoglobin A1c (HbA1c) levels controlled is 49.4%(1). Among patients taking oral anti-diabetic drugs, fasting plasma glucose and 2-hour postprandial plasma glucose level lower than or equal to target were only achieved by 51.3% and 53.4%, respectively. These observations from real-world data highlights the unmet medical needs in diabetes, and are the reasons why biotech companies continue to explore novel therapies to improve diabetes management. With a novel mechanism of action, dorzagliatin is an investigational first-in-class glucokinase activator (GKA) targeting the restoration of glucose homeostasis in T2DM patients by addressing the defect of the glucose sensor function in the pancreas. A recently completed phase III clinical study of dorzagliatin monotherapy by Hua Medicine showed positive 52-week efficacy data. In addition, 24-week topline results were announced recently: The phase III metformin combination clinical trial met the primary efficacy endpoint.

We are very excited to have this great opportunity, joining forces with Bayer to bring a first-in-class diabetes medicine, dorzagliatin, to Chinese patients, said Dr. Li Chen, CEO of Hua Medicine. Bayer has been a leader in diabetes treatment for the past 10 years in China and will be a great partner for Hua Medicine to advance diabetes care. T2DM currently affects approximately 463 million patients worldwide, 116 million of which are in China(2). Over the last ten years, Hua Medicine has translated the novel concept of glucose homeostasis management into a breakthrough T2DM therapy that aspires to cure diabetes. For the first time, a drug has demonstrated, in clinical trials, the potential ability to improve glucose metabolism and Bata-cell function in T2DM patients. The partnership between Hua Medicine and Bayer will bring this medical innovation to a broader patient population in China even faster.

Under the terms of the agreement, Hua Medicine as the market authorization holder shall be responsible for clinical development, registration, product supply and distribution, whilst Bayer as the promotion service provider shall be responsible for marketing, promotion and medical education activities in China. Hua Medicine will receive an upfront payment of RMB 300 million and additional payments could reach up to RMB 4.18 billion if certain milestones are met. Bayer receives the exclusive rights to commercialize the product in China and will receive tiered service fee based on the net sales. Initially, both parties will share equally in sales derived from China net sales, with adjusting sales percentages based on agreed China net sales thresholds.

China is a key focus of Bayers partnering efforts and we are continuously looking for assets and health technologies to help address significant unmet medical needs of patients, said Marianne De Backer, PhD, Member of the Executive Committee and Head of Strategy and Business Development & Licensing, Pharmaceuticals Division of Bayer AG. Through this new partnership, we further expand treatment options for millions of Type 2 diabetes patients in China by leveraging our commercial expertise and diabetes leadership position in China and combining it with the external know-how of a strong partner.

The Pharmaceuticals Business Development & Licensing team of Bayer facilitated this collaboration.

(1). British Medical Journal. Prevalence of diabetes recorded in China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study.https://www.bmj.com/content/369/bmj.m997(2). International Diabetes Federation. 9th Edition of IDF Diabetes Atlas.https://www.diabetesatlas.org/en/

About DorzagliatinDorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with T2DM. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with T2DM and serve as a standard-of-care therapy for the treatment of the disease, or as a combination therapy with currently approved anti-diabetes drugs. For more information, please go towww.huamedicine.com

About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go towww.bayer.com.

About Hua MedicineHua Medicine is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes to satisfy unmet medical needs. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its primary endpoint in both of its Phase III monotherapy and combination trials in China over the 24-week trial period, and completed its 52-week Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.

Contact Bayer:Bayer China Communications PharmaceuticalsTel No.: (86)10-5921-8499Email:pharma.china.comm@bayer.com

Contact Hua MedicineInvestors:ir@huamedicine.comMedia:pr@huamedicine.com

Bayer Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayers public reports which are available on the Bayer website atwww.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Hua Forward-Looking StatementsThis press release may contain statements that constitute forward-looking statements, including, but not limited to, statements relating to the implementation of strategic initiatives, and other statements relating to Hua Medicines future business development and economic performance. While these forward-looking statements represent Hua Medicines judgments and future expectations concerning the development of business, a number of risks, uncertainties and other statutory requirements may render actual developments and results to differ materially from our expectations. For more information, go towww.huamedicine.com.

More here:
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment...

Read More...

Nationwide Analysis Details Risk of COVID-19-Related Death in Type 1, Type 2 Diabetics – Endocrinology Network

Monday, August 17th, 2020

An analysis of data from more than 61 million patients is shedding light on the associations of type 1 and type 2 diabetes, respectively, with coronavirus disease 2019 (COVID-19)-related mortality.

Led by investigators at the Imperial College of London, results of the nationwide analysis found both type 1 and type 2 diabetes were associated with a significant increase in odds of in-hospital mortality with COVID-19.

The findings of the study have important implications for people with diabetes, health-care professionals, and policy makers, wrote study investigators. We encourage the use of these findings, along with those from other studies investigating risk factors for COVID-19-related outcomes, to provide reassurance for young people who are at low absolute risk, despite having diabetes.

While the impact of diabetes status and hyperglycemia have been a major topic of interest for clinicians and researchers during the ongoing pandemic, relatively few studies have examined the risks for type 1 and type 2 diabetes, respectively. With this in mind, investigators designed their study to assess the effects of diabetes status and type on in-hospital death in patients with COVID-19 from March 1-May 11, 2020.

Using NHS data from those registered with a general practice in England and alive on February 16, 2020, investigators identified 61,414,470 individuals for inclusion in their analysis. Of these patients, 0.4% (n=263,830) had a diagnosis of type 11 diabetes, 4.7% (n=2,864,670) had a diagnosis of type 2 diabetes, and 0.1% (n=41,750) had other types of diabetes.

During the study period, 23,698 in-hospital COVID-19-related deaths were recorded. Of these deaths, 31.4% (n=7434) had type 2 diabetes, 1.5% (n=364) had type 1 diabetes, and 0.3% (n=69) had other forms of diabetes. Investigators pointed out the unadjusted mortality rates per 100,000 people over the 72-day study period was 27 (95% CI 2728) for those without diabetes, 138 (124153) for those with type 1 diabetes, and 260 (254265) for those with type 2 diabetes.

In analyses adjusting for age, sex, deprivation, ethnicity, and region, patients with type 1 diabetes were at more than a 3-fold increase of in-hospital COVID-19-related death compared tot hose without diabetes (OR, 3.51; 95% CI, 3.16-3.90). In these same analyses, type 2 diabetics were 2 times more likely to experience in-hospital COVID-19-related death (OR, 2.03; 95% CI, 1.97-2.09). Upon adjustment for previous hospital admissions with coronary heart disease, cerebrovascular disease, or heart failure, the odds for in-hospital COVID-19-related death for type 1 diabetics were 2.86-times greater and the odds for patients with type 2 diabetes were 1.80-times greater when comparing these groups to nondiabetic patients.

For older people who are at higher absolute risk, the results can inform public guidance, including recommendations for shielding, wrote investigators. Further elucidation of the modifiable risk factors for poorer COVID-19 outcomes in people with diabetes will be crucial in guiding management and providing targeted support.

This study, Associations of type 1 and type 2 diabetes with COVID-19- related mortality in England: a whole-population study, was published in The Lancet: Diabetes & Endocrinology.

Link:
Nationwide Analysis Details Risk of COVID-19-Related Death in Type 1, Type 2 Diabetics - Endocrinology Network

Read More...

Amid COVID-19, people with diabetes struggle to get insulin – Los Angeles Times

Sunday, August 16th, 2020

For Adam Winney, a 26-year old with Type 1 diabetes, grocery shopping during the early days of a pandemic was an infuriating task. Everything was sold out, except for the one type of food he couldnt eat.

The only things left were carbs, carbs, carbs, the Van Nuys resident said. Ive never been more furious than back in March.

For the record:

1:54 PM, Aug. 11, 2020A previous version of this story said an insulin pump delivers insulin to the pancreas of a person with Type 1 diabetes. The pump actually infuses the insulin under the skin so it can be absorbed into the bloodstream.

Winneys disease has deprived his body of insulin, a hormone thats needed to turn the sugar in carbohydrates into energy. Without it, his blood sugar can spike to dangerous levels, eventually leading to serious health problems like cardiovascular disease, nerve damage and kidney failure.

But the insulin pens he relies on to keep his body in balance cost him upwards of $1,000 a month, since his health insurance doesnt cover the medication. After the coronavirus outbreak cost him his job as a receptionist at a hair salon, that expense was beyond his reach. He went six weeks without the long-acting insulin he usually takes every day.

I was fighting nausea every morning, he said, a sign that his body was susceptible to diabetic ketoacidosis, a state of dangerously high blood sugar levels that has landed him in the hospital before. Your body just falls apart.

Newsletter

Get our free Coronavirus Today newsletter

Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.

Enter Email Address

Sign Me Up

You may occasionally receive promotional content from the Los Angeles Times.

COVID-19 presents a unique set of challenges to the roughly 34 million Americans like Winney who are living with diabetes.

The Centers for Disease Control and Prevention says people with Type 1 diabetes are probably more susceptible to a severe case of COVID-19. Those with Type 2 diabetes the more common form that begins when people lose their sensitivity to insulin are definitely at increased risk of severe COVID-19, according to the CDC.

For instance, a study of more than 7,300 COVID-19 patients in China found that those with Type 2 diabetes needed more medical care and were nearly 50% more likely to die than patients without diabetes. The risk of death was especially high for people who had trouble controlling their blood sugar, researchers reported. Another study of more than 1,200 COVID-19 patients in the U.S. found that the mortality rate for those with diabetes or high blood sugar was 29%, compared with 6% for those without diabetes.

The extent to which you control your diabetes is a risk factor, said Dr. Daniel Drucker, a senior scientist at the Lunenfeld-Tanenbaum Research Institute at the University of Toronto. Theres a lot we can do about that, by making sure that your diabetes is optimally controlled.

Insulin is essential for keeping blood sugar in check, but the pricey medicine is harder to get if a job disappears, along with the health insurance that came with it.

The cost of insulin varies from patient to patient. It depends on the type of insulin they need some take effect within 15 minutes; others last more than a day as well as the dose. Some insurance plans pick up more of the tab than others.

The financial strain brought on by the pandemic has forced Royce Jonathan Miller of Yuba City to consider rationing the insulin he takes for Type 1 diabetes. He has kept his job as an optician at Walmart, but since his father-in-law lost his job at a maintenance company that closed operations due to the pandemic, Miller has become the sole provider for the four people in his household.

Brandi DaVeiga programs the insulin pump that helps her control her Type 1 diabetes.

(Christina House / Los Angeles Times)

Miller has an insulin pump, which uses a tube to infuse a small amount of insulin under the skin so it can be absorbed into the bloodstream. He is supposed to change out the pieces that connect to his body every three days. Lately, hes been wondering if thats absolutely necessary.

Im starting to think, I can stretch that up for two cycles, every six days, and hopefully it doesnt get infected, Miller said. But I do realize that if I am to make myself sick and wind up in the hospital, that will be a bigger burden.

A nationwide survey of 5,000 people with diabetes conducted for the American Diabetes Assn. found that one in four have rationed supplies to cut the cost of their diabetes care since the start of the pandemic.

Now is not the time to let up on helping these individuals manage their disease, because it may in fact be helpful in preventing them from getting severe COVID-19, Drucker said.

People with Type 2 diabetes may face even greater hardship in affording their insulin, said Dr. Francisco Prieto, a family health physician in Sacramento.

Not everyone who has Type 2 has to take insulin, Prieto said. Those who do are typically folks who either have the most severe cases of diabetes or have failed all the previous oral and injectable treatments. That means they may need to take even more insulin on a daily basis than Type 1 patients, he said.

Since 2019, 11 states have set limits on the amount insurance companies can set as co-payments for insulin. Each of those states has enacted price caps ranging from $25 to $100 per month since the coronavirus outbreak took off in March.

California may soon join the list. In February, Assemblyman Adrin Nazarian (D-North Hollywood) introduced a bill that would cap insulin co-pays at $50 for a 30-day supply, or $100 per month. It passed in June by a 64-4-11 vote, but the Senate Health Committee has not scheduled a hearing that would allow the bill to move forward.

Winney said a price cap would give him some peace of mind. These days he relies on free samples provided by one of his doctors, but that generosity may not last.

I see that as an incentive to finally change insurance, he said.

Brandi DaVeiga, who has Type 1 diabetes, at home in Lakewood.

(Christina House / Los Angeles Times)

Ensuring an affordable supply of insulin would help people with diabetes manage their disease better, said Brandi DaVeiga, a stay-at-home mom in Lakewood with Type 1 diabetes. She has good coverage now through her husbands health insurance plan, but when she was between plans three years ago, she began skipping insulin doses to make her supply last longer. On several occasions, her blood sugar levels rose dangerously high, and she ended up in the emergency room.

Its really stressful, she said of managing diabetes during a pandemic. And that doesnt help your blood sugar.

The fact that people with diabetes are rationing their insulin when they need it most points to larger problems with healthcare access in this country, Drucker said.

COVID-19 is reminding us of the importance of doing everything we can in our vulnerable, at-risk populations, he said. Lets do everything we can to optimize their health because that may, in turn, reduce their risk of having a bad outcome with this virus.

Here is the original post:
Amid COVID-19, people with diabetes struggle to get insulin - Los Angeles Times

Read More...

Distinguishing between type 1 and type 2 diabetes – The BMJ

Sunday, August 16th, 2020

In patients with new onset hyperglycaemia where the type of diabetes is ambiguous, diabetes specific autoantibodies are the diagnostic test of choice to distinguish between type 1 and type 2 diabetes

Patients with newly diagnosed diabetes who are over 40 and respond well to oral anti-hyperglycaemic therapy do not need to undergo testing to distinguish between type 1 and type 2 diabetes

Glycated haemoglobin (HbA1c) is not recommended as a diagnostic test for patients with possible or suspected type 1 diabetes because it may not reflect a recent rapid rise in blood glucose and results take longer than with serum glucose testing

A 33 year old man with no notable medical history attends his general practitioner reporting two months of fatigue, with no other symptoms. His mother has hypothyroidism. His body mass index is 25 kg/m2 and he has a pulse rate of 72 beats/min and blood pressure 135/88 mmHg with no postural drop. Examination is unremarkable. A random blood glucose test shows 14 mmol/L (250 mg/dL). Urinalysis is normal. The next day the patient returns, and a repeat fasting glucose test finds 14 mmol/L.

This article is intended to help primary care doctors to differentiate between type 1 and type 2 diabetes when first diagnosing diabetes in a patient where the distinction is unclear.

For people who fit the classic pattern of type 2 diabetes (table 1), and where two glucose test results are in the diabetic range (box 1), no further testing is required for diagnosis, and management should follow current guidelines.1 Follow-up testing of glycated haemoglobin (HbA1c) is useful to assess glycaemia over time and to tailor treatment.1

Clinical features at presentation that help to distinguish type 1 and type 2 diabetes

Here is the original post:
Distinguishing between type 1 and type 2 diabetes - The BMJ

Read More...

The Best 7 Foods to Lower Blood Sugar Naturally and Help Burn Fat – The Beet

Sunday, August 16th, 2020

If you want to shed fat faster, the trick is to keep your blood sugar low and turn up the engines by working out.The latesttrend is to "eat like a diabetic" for overall best body fueling, so your system runs on the calories you eat (and working-out puts you at a deficit) so you never have a chance to store extra calories as fat. Nowadays "the diabetic diet" is getting a lot of attention because even for non-diabetics,it's the best wayto eat to reduce or avoid diabetes, which is more critical than ever since diabetes is a known risk factor for serious COVID-19 symptoms. To stay well, slim down and shed unwanted fat layers right now, eating high fiber, plant-based foods that have the lowest glycemic indexis being touted as the best strategy. The added benefit: Along with losing weight these all have anti-viral, immunity-boostingbenefits.

Even if you are not diabetic, and you just want to lower blood sugar and turn up the burners to help your body burn fat, there are foods that can help your body use available energy and not store calories as fat -- naturally. If you choose the right foods, get active, and keep your calories in check, you'll be able to lower your blood sugar levels and help your body's natural ability to metabolize the carbs you eat, to use blood sugar as fuel, and not allow insulin to signal "too much sugar here.... put this extra stuff into storage!" The key to doing this is to eat the foods that best keep blood sugar levels steady, or better yet, nice and low, and not let your insulin levels surge, since it's that signal that starts your body crating off calories to fat.

These foods are known to damp down blood sugar and turn off the insulin sirens, to help you burn fat naturally. We found this list in TimesNowNews.comand added two of our favorites to bring you the 7 best plant-based foods to lower blood sugar and burn fat naturally.

See the rest here:
The Best 7 Foods to Lower Blood Sugar Naturally and Help Burn Fat - The Beet

Read More...

4 of the best ways to treat diabetes and lower blood sugar – Insider – INSIDER

Saturday, August 15th, 2020

No matter what type of diabetes you have, the goal of diabetes treatment is to control blood sugars and keep them within the healthy range.

Type 1 diabetes must be treated with insulin, since the pancreas does not produce insulin naturally. People with type 2 or gestational diabetes don't always need insulin treatment, and will often focus on lifestyle changes and oral medications that encourage insulin production or decrease insulin resistance.

With proper access to healthcare, diabetes is highly treatable, says Katherine Araque, MD, an endocrinologist and director of endocrinology of the Pacific Neuroscience Institute at Providence Saint John's Health Center in Santa Monica, California.

Here are the four main ways you can treat and manage your diabetes.

Insulin is a hormone produced in the pancreas in healthy individuals. It helps facilitate the process of converting blood sugar into fuel, so that glucose doesn't build up in the blood.

In people with type 1 diabetes, the pancreas cannot produce insulin, so they need synthetic insulin. This can happen in two ways:

People with type 2 diabetes are treated with insulin when they are unable to control their blood glucose levels with lifestyle changes and medication. Overall, roughly 24% of people with diabetes are treated with insulin, according to a 2018 study published in Diabetes Care.

If you need insulin, your doctor will provide specific guidance on how much you need and when you should take it.

Although people with type 1 diabetes will need insulin, they may also be prescribed medication if they have some remaining pancreas function. The medication can encourage insulin production in the body.

People with type 2 diabetes are prescribed medication when they can't control their blood sugars through diet and exercise. Oftentimes, people with type 2 diabetes use more than one medication to control their condition.

However, medications are usually not recommended for pregnant people with gestational diabetes.

Common medications used to treat diabetes include:

Metformin is the most common medication used to treat type 2 diabetes. It's sometimes used to treat type 1 diabetes in people who still have some insulin production, along with insulin.

Metformin helps control blood sugar by making it easier for the body to absorb glucose. It's usually taken twice a day, with meals. Even when used alone, metformin can reduce A1C levels by 1.5% on average, which is enough to drop blood sugar levels from diabetes to prediabetes.

Sulfonylureas are a class of drugs that encourage the pancreas to release more insulin. They're used to treat type 2 diabetes. They are often taken once or twice a day before meals.

Sulfonylureas have a similar efficacy to metformin, and can be used alongside it.

TZDs make it easier for the body to use insulin; they reduce insulin resistance. They can be used to treat type 2 diabetes. They are taken 1 to 2 times per day.

After a year of taking TZDs, people with type 2 diabetes reduced their A1C levels by 1.4%, according to a 2019 study published in Vascular Health Risk Management.

Exercise is important for people with all types of diabetes. "Exercise helps at multiple levels: it increases base metabolic rate, fights insulin resistance, and helps with weight loss," says Araque.

Exercise helps muscles burn glucose and reduces insulin resistance. When you exercise, your muscles burn more glucose, removing it from the bloodstream and helping to lower blood sugar levels.

For example, a 2017 study published in Biomedical Research followed 120 obese teens, who did two hours of aerobic exercise twice a day for six days a week. After five weeks, their average fasting blood sugar was reduced by 0.84 nanomoles per liter (nmol/L) for males and 1.04 nmol/L for females. The researchers described this as "an extremely significant difference."

The Center for Disease Control and Prevention (CDC) recommends that people with diabetes get the normally recommended amount of exercise: 150 minutes of exercise each week, including two days of strength workouts that incorporate major muscle groups. The American Diabetes Association recommends starting with small changes, like walking daily.

Any exercise will help, but some may be especially beneficial. For example, a 2019 study published in Diabetologia found that afternoon exercise decreased blood sugars more than morning exercise.

Overall, you should work with your doctor to identify an exercise program that will benefit you, Araque says.

Healthy eating is critical for people with diabetes. As food breaks down, it releases glucose into your blood. Some foods, including processed sugars and carbohydrates, raise blood sugars more than other foods, like proteins or leafy vegetables.

In particular, people with diabetes need to be aware of how many carbs they eat per day. They should also create an eating plan that includes the following:

For example, the DASH diet and Mediterranean diet which both emphasize healthy fats, lean protein, protein and vegetables have been proven to help people with type 1 and type 2 diabetes control blood sugar.

Read more about the best ways to eat if you have diabetes:

Diabetes is a chronic but manageable condition, Araque says. People with diabetes should work with their doctor, nutritionist, and an exercise professional to design a program that meets their needs.

"The most important message is if they follow these recommendations they can get this under control and decrease risk for complications," Araque says. "Patients should have hope."

Read the original post:
4 of the best ways to treat diabetes and lower blood sugar - Insider - INSIDER

Read More...

MENTAL HEALTH MATTERS: Depression and diabetes: Are they linked? – Sherman Denison Herald Democrat

Saturday, August 15th, 2020

Recent research in the Journal of Medicine (2016) has shown us that rates of depression can be twice as high in people with type 2 diabetes than in the general population. So, whats the missing link here? Why do people with diabetes tend to experience more issues with depression?

To start, the Stand American Diet is closely tied to the development of T2D. In a study published in 2017, people who regularly consumed red meat, processed meat, sugar sweet beverages (SSB), and eggs showed to have two times the risk of T2D. Also, people who added to their diet whole grains, vegetables, fruits, and dairy showed a 42% reduction compared to the prior group. Perhaps most amazing in this study is that people who combined both not eating the unhealthy foods and adding in the healthy foods, showed a whopping total risk reduction of 70%! (European Journal of Epidemiology).

Now, consider that studies have also shown that the Standard American Diet is tied to depression. High consumption of red and/or processed meat, refined grains, sweets, high-fat dairy products, butter, potatoes and high-fat gravy, and low intakes of fruits and vegetables is associated with an increased risk of depression (Psychiatry Research 2017). Alcohol, as well, can play a part given that increased use has shown an increased risk of depression (Addiction 2011). Epidemiological evidence suggests a strong connection between diet quality and mental health across multiple populations and age groups (the Nutrition Society 2017).

Diabetes is a chronic health condition that prevents insulin from allowing glucose into muscle cells in the body. Glucose (a monosaccharide sugar) is the major energy source of the body. People with type two diabetes (T2D) cannot properly use the insulin their bodies make, resulting in too much glucose circulating in the bloodstream. Over time, this can cause serious health problems. In 1958, less than one percent of the U.S. had diabetes. By 2019, that number had grown to 13% a 1200% increase!

It has also been suggested that the effect of exercise also may be comparable to antidepressant medication and psychotherapy for mild to moderate depression. As well, exercise seems to be a valuable complementary therapy to the traditional treatments for severe depression (Disability Rehabilitation, 2015). Other studies have also shown that unhealth eating habits along with tobacco smoking and lower levels of physical activity are major contributors to chronic disease and mortality (Schizophrenia Research, 2018).

What all of this tells us that the missing link between depression and type 2 diabetes is something we actually have some control over. Simply lifestyle choices that we can make can prevent the majority of T2D and have profound effects on depression symptoms. Eating a healthy diet, not smoking, low consumption of alcohol, and moderate exercise can reduce the risk of T2D by 91% (New England Journal of Medicine). Changing what we eat can actually provide a clinically significant benefit to traditional forms of treatment for both diabetes and depression.

Jim Runnels is a retired Licensed Professional Counselor and advocate of evidence-based education and supporter of the health benefits of a whole food plant-based, active lifestyle, to achieve optimal health. He is the administrator of Eat Healthy-Texoma Facebook page. The views and opinions expressed here are the authors own and do not necessarily reflect those of the Herald Democrat.

Here is the original post:
MENTAL HEALTH MATTERS: Depression and diabetes: Are they linked? - Sherman Denison Herald Democrat

Read More...

Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim – Medscape

Saturday, August 15th, 2020

Diabetes increases the risk of kidney cancer in postmenopausal women, but paradoxically, only in nonobese women, as defined by body mass index (BMI) and waist circumference, according to a new analysisfrom the Iowa Women's Health Study (IWHS).

"Many studies have linked a history of diabetes to the increased risk of kidney cancer [but] it is unclear whether diabetes is a risk factor for kidney cancer independent of other risk factors such as obesity and hypertension," write Shuo Wang, PhD, of the School of Public Health, University of Minnesota, Minneapolis, and colleagues.

"[While we found that] an association between diabetes and kidney cancer was not statistically significant among the whole cohort...a positive, statistically significant association was observed among nonobese women (BMI < 30 kg/m2) or waist circumference < 34.6 inches (87.9 cm)," the authors suggest.

And although they acknowledge "these findings should be validated in larger or pooled prospective studies," they stress that "patients with new-onset diabetes may require more thorough surveillance for cancer including kidney cancer."

The results were published online August 11 in Maturitas.

The IWHS was launched in 1986 when a baseline questionnaire was completed by a total of 41,836 women.

Subsequent questionnaires were mailed in 1987, 1989, 1992, 1997, and 2004, returned by increasingly fewer respondents over the years.

The cohort for the current analysis included 36,975 women, mean age of 61.7 years, 6.4% of whom reported adiabetes diagnosisat baseline.

"At baseline, diabetes status was determined for each participant by one of two ways," the researchers explain.

Women were first asked if a physician had ever told them they had diabetes and were also asked whether they took pills for diabetes and/or insulin. A tape measure was included with the baseline questionnaire and women were asked to have their waist measured in a precise manner with a high degree of accuracy and reliability.

Between 1986 and 2011, investigators identified 257 cases of kidney cancer in their cohort.

They then examined the association between baseline and time-dependent diabetes and kidney cancer risk using three models, the first adjusted only for age, the second adjusted for age and BMI tertile, and the third was a multivariable-adjusted model.

The adjusted variables in the third model included age and indices of obesity, as reflected by BMI and waist-to-hip ratio (WHR), as well as physical activity levels, pack-years of smoking, total caloric intake, presence of hypertension, diuretic use, and alcohol intake.

Cutoffs used to define obesity included a BMI of 30 kg/m2, a WHR of 0.85, and a waist circumference of 34.6 inches.

Researchers also analyzed the association between duration of diabetes and kidney cancer risk using a nested-case control design within the IWHS cohort.

Over the course of follow-up, an additional 8.5% of women reported a new diagnosis of diabetes.

"Several characteristics were statistically significantly associated with kidney cancer risk," the authors note (Table 1).

"And time-dependent diabetes was associated with an increased risk of kidney cancer in models 1 and 2," they added.

Table 1. Increased Kidney Cancer Risk, Baseline Characteristics (Models 1, 2)

*4 grams/day of alcohol

BMI = body mass index; WHR = waist-hip ratio

However, when investigators adjusted the association between time-dependent diabetes and kidney cancer risk in model 3, associations seen in models 1 and 2 were attenuated and no longer significant, the authors underscore.

In contrast, the risk of kidney cancer increased for women with diabetes.

Compared to women without diabetes, women with diabetes and a BMI < 30 kg/m2 had an 82% higher risk of kidney cancer, and those with diabetes and a waist circumference < 34.6 inches had an over twofold greater risk (Table 2).

Table 2. Interaction Between Diabetes, Weight in Kidney CaRisk (Model 3)

BMI = body mass index; HR = hazard ratio; WC = waist circumference

As the investigators point out, there are a number of possible explanations for these seemingly paradoxical findings.

Type 2 diabetes is associated with high blood glucose, which itself may increase uncontrolled cell growth and division.

This may help explain why investigators saw a stronger association with kidney cancer among those with a shorter diabetes duration, that is, "those who are more likely to have uncontrolled diabetes," they explain.

Investigators also point out: "Patients with type 2 diabetes (the majority of diabetes cases in our study) have high serum levels of insulin that promote the secretion and production of insulin-like growth factor 1 (IGF-1)."

IGF-1 is important in the regulation of cell proliferation and differentiation, and thus may promote the formation and growth of cancer, they add.

But there is a "nonlinear relationship between BMI and IGF-1 levels," the investigators observe. For example, one study found that IGF-1 concentrations in women increased as BMI increased up to a maximum of 26 kg/m2, after which IGF-1 concentrations decreased among women with higher BMIs.

"In line with this finding, we found an association among nonobese women...even in the fully adjusted model, but observed no association between diabetes and kidney cancer among obese women...which could be explained by lower levels of IGF-1 among obese women."

Previous epidemiologic findings from the IWHS did find evidence of an association between weight-related measures and kidney cancer risk; however, those with a BMI in the top quartile had an almost 2.5-fold greater risk of kidney cancer than those in the lowest BMI quartile.

The study was funded by the National Cancer Institute. The authors have reported no relevant financial relationships.

Maturitas. Published online August 11, 2020. Abstract

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

More here:
Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim - Medscape

Read More...

How to lower your blood sugar quickly and what to do if it’s an emergency – Insider – INSIDER

Saturday, August 15th, 2020

If you have diabetes, your body isn't able to regulate blood sugar properly, either because the pancreas doesn't produce insulin (type 1 diabetes) or the body has become resistant to it (type 2 diabetes).

As a result, people with diabetes have to carefully manage their blood sugar levels through diet, exercise, and medications to make sure it stays in a healthy range.

But sometimes, blood sugar can become too high. In many of these cases, people with diabetes will be able to quickly lower blood sugar on their own, by taking more insulin. However, other times, they may need to visit the ER for immediate medical attention.

Here's how to tell if your blood sugar is too high and what you'll need to do in order to lower it quickly.

People with diabetes are considered to have high blood sugar, or hyperglycemia, if blood glucose levels are higher than:

While there are other conditions that can cause hyperglycemia, it is most commonly linked to both type 1 and type 2 diabetes. That's why it is important for people with diabetes to check their blood sugar using blood glucose meters with the goal of keeping levels from getting too low or too high.

In addition, there are other signs and symptoms of high blood sugar you might notice.

The most common symptoms of hyperglycemia are:

"If someone has hyperglycemia, it would mean they would be very thirsty, tired, they might be urinating more frequently and basically not feeling well," says Sam Zager, M.D. a family medicine physician in Maine.

Hyperglycemia is not automatically an emergent situation. Anyone with diabetes knows high blood sugar readings will happen, and it's okay, as long as it doesn't last too long or get too high.

If it does occur, here are a few ways to quickly lower blood sugar on your own:

Insulin can be used to treat acute cases of high blood sugar for people with diabetes.

People with type 1 diabetes (who always use insulin) and some people with type 2 diabetes (who sometimes use insulin) can give themselves an extra dose of insulin to quickly lower their blood sugar to safer levels. How much to take depends on the situation and what your doctor recommends.

When you have high blood sugar, you may experience frequent urination as your body tries to get rid of the extra glucose. Losing this fluid can cause dehydration and make hyperglycemia symptoms even worse.

It's important to drink water when you have hyperglycemia in order to stay hydrated and help your body regulate and lower blood sugar. But drinking lots of water won't necessarily lower blood sugar on its own. For more information, read about how much water you're supposed to drink a day.

Exercise isn't always the safest or most effective way to quickly lower blood sugar. It is important to note that exercise only works if there is insulin present, whether naturally or through injection, so that glucose can get into the cells to be metabolized.

If there is no insulin, your body will start burning fat for energy, and this could lead to a dangerous condition called diabetic ketoacidosis. People with type 1 diabetes should not exercise if they have hyperglycemia.

However, exercise can lower blood sugar for most people with diabetes it just shouldn't be used in emergency situations. In a 2013 study in the journal Diabetes Care, more than 5,000 people with diabetes recorded their blood glucose levels before and after exercising for as little as 10 minutes. Overall, more than 75% of people saw their level decrease an average of about 17%.

Overall, Zager says that exercise is important for managing diabetes, but warns that it isn't a great short-term fix. For more information on how to control blood sugars in the long-term, learn about the 6 best ways to lower blood sugar naturally.

For people with type 1 diabetes, untreated high blood sugar can lead to a life-threatening condition called diabetic ketoacidosis, or DKA.

When there is no insulin and glucose can't get into cells, your body starts breaking down fat into a fuel called ketones. If ketones build up in your blood, it becomes dangerously acidic. DKA can cause very serious health complications such as fluid building up in the brain, kidney failure, and cardiac arrest.

If your blood sugar is above 240 mg/dL, you should check your urine for ketones, a sign you may be at risk for DKA. You can do this with an at home test, but you also should contact your doctor. If there are ketones in your urine, you should go to the emergency room. Other symptoms of DKA include:

In rare occasions, DKA can occur in people with type 2 diabetes, but the more common complication for people with type 2 is called hyperglycemic hyperosmolar state, or HHS. HHS occurs when blood glucose levels are high for an extended period of time. The extra sugar is passed into the urine, causing the person to urinate frequently and become severely dehydrated, just like with DKA.

For people with type 2 diabetes, blood sugar above 600 mg/dL indicates HHS. Other symptoms include:

These symptoms generally come on slowly, but you should contact your doctor immediately. In the ER, doctors will likely use insulin to lower your blood sugar, as well as give you fluid and electrolytes, to keep your heart, kidneys, muscles, and nerve cells functioning properly.

For people with diabetes, a single instance of high blood sugar is generally not an emergency, as long as it is addressed. Usually, taking an extra dose of insulin will quickly lower your blood sugar back to normal levels. However, if you are on insulin and run out, or have symptoms of DKA or HHS, you should get medical attention right away.

Read the rest here:
How to lower your blood sugar quickly and what to do if it's an emergency - Insider - INSIDER

Read More...

Page 18«..10..17181920..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick